Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.49 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.49 |
| ▸ | FADS1 | O60427 | 2/20 | 0.48 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512039 | 0.82 | ALDH1A1 (0.54) | PTGS1PTGS2ABL1PRKCAPRKCD | |
| SCHEMBL2559581 | 0.80 | FADS1 (0.49) | PTGS1PTGS2ERBB2PTK6FADS1 | |
| SCHEMBL27485674 | 0.78 | ALDH1A1 (0.41) | PTGS1PTGS2ALDH1A1GAARAB9A | |
| SCHEMBL4714454 | 0.78 | PTGS1 (0.59) | PTGS1PTGS2ERBB2PTK6FADS1 | |
| SCHEMBL28933599 | 0.76 | EGFR (0.53) | ERBB2FADS1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL4905987 | 0.76 | AKR1C3 (0.59) | PTGS1PTGS2HIPK2PIM1PIM2 | |
| SCHEMBL4717840 | 0.75 | ALDH1A1 (0.70) | PTGS1PTGS2ERBB2PTK6FADS1 | |
| SCHEMBL11593946 | 0.75 | PTGS1 (0.70) | PTGS1PTGS2ERBB2PTK6FADS1 | |
| SCHEMBL6643061 | 0.72 | NPC1 (0.59) | ERBB2FADS1MEN1KMT2AALDH1A1 | |
| SCHEMBL15332714 | 0.72 | HDAC3 (0.59) | PTGS1PTGS2ERBB2PTK6ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642250-B2 | As phosphodiesterase inhibitor for prophylaxis and therapy of bronchial asthma; pneumonic diseases, pulmonary emphysema, chronic obstructive pulmonary disease acute respiratory distress syndrome (ARDS), and other respiratory diseases | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030036651-A1 | Novel 1,8-naphthyridin-2(1h)-one derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036651-A1 | Novel 1,8-naphthyridin-2(1h)-one derivatives | PDE3B, PDE4A, PDE4B | PTGS1 75/4885PTGS2 225/4885ERBB2 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.